

Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment

Authors

Oudai Alkabbani,¹ Yazan Jabban,¹ Rong He,² David Viswanatha,² Kurt Bessonon,³ Patricia Greipp,² Dragan Jevremovic,² James M. Foran,⁴ Talha Badar,⁴ Cecilia Arana Yi,⁵ Yael Kusne,⁵ Antoine N. Saliba,¹ Mehrdad Hefazi Torghabeh,¹ Aasiya Matin,¹ William J. Hogan,¹ Abhishek Mangaonkar,¹ Hassan Alkhateeb,¹ Mrinal Patnaik,¹ Mithun Shah,¹ Kebede Begna,¹ Mark R. Litzow¹ and Aref Al-Kali¹

¹Division of Hematology, Mayo Clinic, Rochester, MN; ²Division of Hematopathology, Mayo Clinic, Rochester, MN; ³Division of Molecular Hematology, Mayo Clinic, Rochester, MN; ⁴Division of Hematology, Mayo Clinic, Jacksonville, FL and ⁵Division of Hematology, Mayo Clinic, Phoenix, AZ, USA

Correspondence:

A. AL-KALI - alkali.aref@mayo.edu

<https://doi.org/10.3324/haematol.2025.288105>

Received: April 28, 2025.

Accepted: July 11, 2025.

Early view: July 17, 2025.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license



Figure (S1)

Frequencies of mutations in untreated patients.




Figure (S2)

Reasons for not receiving therapy.




Figure (S3)

Overall survival analysis in untreated patients based on different cytogenetic and molecular characteristics.

